Edwards Lifesciences (EW) PT Raised to $85 at Barclays

Go back to Edwards Lifesciences (EW) PT Raised to $85 at Barclays

Goldman Sachs Reiterates Buy Rating on Edwards Lifesciences (EW)

October 30, 2024 4:16 PM EDT

Goldman Sachs analyst David Roman reiterated a Buy rating and $80.00 price target on Edwards Lifesciences (NYSE: EW).

The analyst comments "Overall, we think confirmatory results for the full cohort of TRISCEND II was broadly expected by investors we have spoken... More

BofA Securities Reiterates Neutral Rating on Edwards Lifesciences (EW)

October 30, 2024 4:03 PM EDT

BofA Securities analyst Travis Steed reiterated a Neutral rating and $75.00 price target on Edwards Lifesciences (NYSE: EW).

The analyst comments "On Wednesday EW hosted a TMTT investor event after Evoque pivotal data were presented. See TRISCEND II at TCT report for our initial take on the data. We go over the key... More

Bernstein SocGen Group Upgrades Edwards Lifesciences (EW) to Market Perform

October 28, 2024 8:19 AM EDT

Bernstein SocGen Group analyst Lee Hambright upgraded Edwards Lifesciences (NYSE: EW) from to Market Perform.

The analyst comments "Our previous Underperform call on EW was based on the view that the TAVR market was experiencing slowing growth and increased competition. Now as... More